MicroRNA-221/222 Upregulation Indicates the Activation of Stellate Cells and the Progression of Liver Fibrosis
Overview
Authors
Affiliations
Background: MicroRNAs (miRNAs) are important in hepatic pathophysiology and the development of liver cancer.
Objective: To explore miRNAs that are regulated with the progression of liver fibrosis caused by chronic liver disease.
Design: The regulated miRNAs in human livers infected with hepatitis C virus were identified by microarray analysis. Their expression in human livers with non-alcoholic steatohepatitis, mouse livers from two fibrosis models and cultured stellate cells was validated by real-time RT-PCR. The regulation of miR-222 expression in stellate cells by nuclear factor kappa B (NF-κB) was assayed. Finally, the effects of an miR-222 precursor or inhibitor on the expression of cyclin-dependent kinase inhibitor 1B (CDKN1B) and the growth of LX-2 cells were determined.
Results: It was found that miR-199a-5p/199a-3p and miR-221/222 were upregulated in the human liver in a fibrosis progression-dependent manner. Among these miRNAs, miR-221/222 were upregulated in LX-2 cells and increased during the course of culture-dependent activation of mouse primary stellate cells, in a manner similar to the expression of α1(I) collagen and α-smooth muscle actin mRNAs. The expression of miR-221/222 increased in mouse models of liver fibrosis. In contrast, an NF-κB inhibitor significantly suppressed the miR-222 induction that was stimulated in culture by transforming growth factor α or tumour necrosis factor α. Although overexpression or downregulation of miR-222 failed to regulate the growth of LX-2 cells, miR-222 bound to the CDKN1B 3'UTR and regulated the expression of the corresponding protein.
Conclusion: miR-221/222 may be new markers for stellate cell activation and liver fibrosis progression.
From fatty liver to fibrosis: the impact of miRNAs on NAFLD and NASH.
Mansour R, Mageed S, Abulsoud A, Sayed G, Lutfy R, Awad F Funct Integr Genomics. 2025; 25(1):30.
PMID: 39888504 DOI: 10.1007/s10142-025-01544-x.
Sartorius K, Wang Y, Sartorius B, Antwi S, Li X, Chuturgoon A Funct Integr Genomics. 2025; 25(1):24.
PMID: 39847120 DOI: 10.1007/s10142-024-01519-4.
Sutradhar P, Sultana N, Nessa A Int J Hepatol. 2024; 2024:4221368.
PMID: 39185365 PMC: 11343628. DOI: 10.1155/2024/4221368.
He L, Xu J, Huang P, Bai Y, Chen H, Xu X Int J Mol Sci. 2024; 25(13).
PMID: 39000343 PMC: 11241704. DOI: 10.3390/ijms25137235.
Farsi N, Naghipour B, Shahabi P, Safaralizadeh R, Hajiasgharzadeh K, Dastmalchi N Clin Exp Hepatol. 2024; 9(4):307-319.
PMID: 38774201 PMC: 11103798. DOI: 10.5114/ceh.2023.131669.